HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

Files in This Item:
bjc.2013.108.pdf1.04 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/53423

Title: Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
Authors: Eto, Kazunori Browse this author
Kawakami, Hiroshi Browse this author →KAKEN DB
Kuwatani, Masaki Browse this author →KAKEN DB
Kudo, Taiki Browse this author
Abe, Yoko Browse this author
Kawahata, Shuhei Browse this author
Takasawa, Akira Browse this author
Fukuoka, Midori Browse this author
Matsuno, Yoshihiro Browse this author
Asaka, Masahiro Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: EUS-FNA
hENT1
Notch3
unresectable pancreatic cancer
Issue Date: 16-Apr-2013
Publisher: NATURE PUBLISHING GROUP
Journal Title: BRITISH JOURNAL OF CANCER
Volume: 108
Issue: 7
Start Page: 1488
End Page: 1494
Publisher DOI: 10.1038/bjc.2013.108
Abstract: Background: Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival in GEM-treated patients by quantifying the expression of several genes in pre-treatment endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) samples from patients with PDC. Methods: The expressions of human equilibrative nucleoside transporter 1 (hENT1), deoxycitidine kinase, ribonucleoside reductase 1, ribonucleoside reductase 2 and Notch3 in EUS-FNA tissue samples from 71 patients with unresectable PDC were quantified using real-time reverse transcription-polymerase chain reactions and examined for correlations with GEM sensitivity. Results: The log-rank test detected no significant differences in overall survival between GEM-treated patients with low and high mRNA levels of all genes examined. However, low Notch3 mRNA expression was significantly associated with longer overall survival in a multivariate analysis for survival (P = 0.0094). High hENT1 expression level was significantly associated with a longer time to progression (P = 0.039). Interaction tests for GEM administration and hENT1 or Notch3 mRNA expression were statistically significant (P = 0.0054 and 0.0047, respectively). Conclusion: hENT1 and Notch3 mRNA expressions in EUS-FNA specimens were the key predictive biomarkers of GEM effect and GEM sensitivity in patients with unresectable PDC.
Type: article (author version)
URI: http://hdl.handle.net/2115/53423
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 河上 洋

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University